

Vimta Labs Limited

Registered Office
142, IDA Phase II, Cherlapally
Hyderabad-500 051, Telangana, India
T : +91 40 2726 4141
F : +91 40 2726 3657



VLL\SE\043\2024-25

Date: 30.08.2024

Listing Centre
B S E Limited
P J Towers, Dalal Street
Mumbai: 400001
Scrip Code No.524394

Asst Vice President
National Stock Exchange of India Limited
"Exchange Plaza", Bandra
Kurla Complex, Bandra (E)
Mumbai – 400051
Trading Symbol: VIMTALABS

Dear Sir/Madam,

Subject: Intimation regarding Company's execution of Business Transfer Agreement ("BTA") with Thyrocare Technologies Limited

Dear Sir/Madam,

This is to inform you that the Company has entered into Business Transfer Agreement ("BTA") on 30th August 2024, around 11.00 AM with, inter-alia, Thyrocare Technologies Limited ("Thyrocare"). By this agreement, our Company will be transferring and selling its Diagnostics and pathological services business to Thyrocare as a going concern (on a slump sale basis). The said transfer is subject to the fulfilment of the Conditions Precedent ("CP").

Details required under Regulation 30 of the Listing Regulations, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July13, 2023, is appended as the Annexure -1 to this Letter.

This is for your information and records.

Thanking you,

Yours faithfully,
for VIMTA LABS LIMITED

Sujani Vasireddi
Company Secretary



Vimta Labs Limited

Registered Office
142, IDA Phase II, Cherlapally
Hyderabad-500 051, Telangana, India
T : +91 40 2726 4141
F : +91 40 2726 3657




Name of the Company: Vimta Labs Limited
VLL\SE\043\2024-25
Date: 30.08.2024

Annexure 1

Disclosure of information pursuant to Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July 2023.

Sr.	Particulars	Disclosures
1	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year.	The turnover of the Diagnostics and pathological services business was Rs 296.67 million, being 9.32% of the consolidated turnover of the company as on 31 st March 2024. Net worth of the business was Rs 21.7 million being 0.69% of consolidated net worth of the company as on 31 st March 2024.
2	Date on which the agreement for sale has been entered into.	30 th August 2024.
3	The expected date of completion of sale/disposal.	Subject to fulfilment of the Conditions Precedent ("CP").
4	Consideration of sale/disposal.	Cash Consideration of Rs 70 million
5	Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof.	Thyrocare Technologies Limited is publicly listed Indian company incorporated in year 2000 and is one of the leading Diagnostic players in India. The buyers do not belong to the promoter/promoter group/ group companies.
6	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length".	No.
7	Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of Listing Regulations.	NA.



Page 2 of 3

Vimta Labs Limited

Registered Office
142, IDA Phase II, Cherlapally
Hyderabad-500 051, Telangana, India
T : +91 40 2726 4141
F : +91 40 2726 3657

8	<p>Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.</p> <p>a. Rationale for Slump Sale.</p> <p>b. Brief details of change in shareholding pattern of Listed entity.</p>	<p>a. The slump sale is on a standalone basis and not pursuant to amalgamation/merger.</p> <p>b. There is no change in shareholding pattern of the listed entity as the slump sale is for cash consideration and not for share exchange ratio.</p>
---	---	--

